The ASX healthcare family tree keeps branching out, often with the same names attached. Pic: Getty Images<\/p>\n
Management and board members of ASX healthcare companies often hold multiple positions across the sector
\nResApp, sold to Pfizer in 2022 for ~$179 million, has left a trail of leaders now involved in multiple ASX healthcare companies
\nLeaders say experience gained from each role strengthens other roles, with a willingness to share expertise a strength of the sector<\/p>\n
\u00a0<\/p>\n
Leadership in the ASX healthcare sector reads much like a family tree, with interconnected branches that keep crossing over.<\/p>\n
Founders often become executives, then directors and investors, with the same names reappearing in boardrooms and on share registries.<\/p>\n
It\u2019s less a coincidence than a feature of a small but experienced ecosystem, where people who have been through the rigours of product development, clinical trials and regulatory approval are in demand and happy to share what they know.<\/p>\n
And while they may collect remuneration for their services, many directors and leaders have skin in the game. They often put their own money into the companies they\u2019re involved in, aligning their interests with shareholders and sitting alongside them when the share price moves in either direction.<\/p>\n
\u00a0<\/p>\n
Roots of the family tree in ResApp<\/p>\n
Leaders behind ResApp Health, which developed a respiratory diagnostics app and left the Aussie bourse in 2022 after being acquired by global healthcare giant Pfizer in a ~$179 million deal, are now supporting other ASX healthcare companies.<\/p>\n
ResApp co-founder and CEO Tony Keating has become an executive director of TrivarX (ASX:TRI)<\/a>, which is focused on developing medical imaging technologies for central nervous system (CNS) oncology applications.<\/p>\n Keating is also an executive director of Ceretas (ASX:CTS)<\/a>, which listed on the ASX in July and is developing a portable, non-invasive therapeutic ultrasound platform to treat Alzheimer\u2019s disease and other neurodegenerative conditions.<\/p>\n \u201cAustralia has a strong pipeline of innovative healthcare technologies, but translating that innovation into a commercially successful business requires a very different set of skills and experience,\u201d\u00a0 he told Stockhead.<\/p>\n \u201cHaving been involved in building ResApp through to its acquisition by Pfizer, I\u2019ve seen firsthand the importance of bringing together the right people, capital and commercial strategy to support a company\u2019s development.<\/p>\n \u201cWhat attracts me to companies like CTS and TRI is the opportunity to apply that experience to emerging technologies with significant clinical and commercial potential.<\/p>\n \u201cThere is a considerable amount of expertise within Australia\u2019s healthcare sector, and I think the willingness of experienced executives and directors to support the next generation of companies is a real strength of the industry,\u201d he said.<\/p>\n \u00a0<\/p>\n Other ResApp alumni share experience<\/p>\n Keating has reunited with founding director of ResApp Chris Ntoumenopoulos, who is also on the board of TRI as a non-executive director.<\/p>\n Ntoumenopoulos also serves as an executive director of IV-infused psilocin therapy developer Entropy Neurodynamics (ASX:ENP)<\/a>.<\/p>\n He is also a non-executive director of antiviral drug developer Island Pharmaceuticals (ASX:ILA)<\/a>.<\/p>\n And let\u2019s not forget another ResApp co-founder, Brian Leedman. He has co-founded and served on the board of multiple ASX healthcare companies and is currently non-executive chairman of Blinklab (ASX:BB1)<\/a>, which is developing a smartphone-based app designed to support clinicians in diagnosing neurodevelopmental conditions such as ADHD and autism.<\/p>\n \u00a0<\/p>\n The Tillett branch of the family tree<\/p>\n Australian biotech entrepreneur Dr Daniel Tillett is the connector on the next branch of the ASX healthcare family tree.<\/p>\n Tillett holds a UNSW PhD in molecular genetics and biochemistry and worked as an academic.<\/p>\n He founded Nucleics, producing and selling world-leading DNA sequencing software to the genomics industry.<\/p>\n He is CEO and managing director of Racura Oncology (ASX:RAC)<\/a>, where Ntoumenopoulos was also a founding director.<\/p>\n He is also a non-executive director of ENP after becoming a cornerstone investor, a significant shareholder in ILA, and a scientific advisor and substantial shareholder in TRI.<\/p>\n Nucleics developed the radiation-free imaging Stabl-Im technology that TRI acquired in November 2025 and is now developing for CNS oncology applications.<\/p>\n Tillett told Stockhead there was more cross-fertilisation between ASX healthcare companies than most investors realise.<\/p>\n \u201cAustralia\u2019s healthcare sector is small, and you keep running into the same people \u2013 as directors, investors, advisors and sometimes as competitors for the same pool of capital,\u201d he said.<\/p>\n \u201cWhether you\u2019re developing a cancer drug, a psychedelic therapy or an imaging technology, the challenges are remarkably similar, including raising capital in a tough market, designing trials that will satisfy regulators, securing manufacturing and finding the right path to market or partnership.<\/p>\n \u201cWhen someone around the board table has already worked through a problem at another company, you don\u2019t have to learn it the hard way.<\/p>\n \u201cThose lessons travel quickly across the sector, and everyone benefits.\u201d<\/p>\n Adding to the experience around TRI, newly appointed CEO Dr Danielle Meyrick has worked across private and public healthcare companies, including senior leadership roles at Telix Pharmaceuticals (ASX:TLX)<\/a>, ITM Isotopes and GenesisCare.<\/p>\n \u201cI am delighted to apply the clinical, drug development and commercial experience I\u2019ve acquired across international biotechs to the TrivarX platform,\u201d\u00a0 Meyrick told Stockhead.<\/p>\n \u201cIt\u2019s a privilege to work alongside an ASX-seasoned board and network, all of whom bring a strong track record of highly relevant success to the extended team.\u201d<\/p>\n \u00a0<\/p>\n Entropy CEO is Island chairman<\/p>\n CEO and managing director of ENP Jason Carroll is also part of this family branch. He is non-executive chairman of ILA, meaning he shares a boardroom with both Ntoumenopoulos and Tillett at each company.<\/p>\n Carroll told Stockhead the Australian biotech sector was relatively small, so it was natural that experienced executives, directors and investors are involved across multiple companies.<\/p>\n \u201cI see that as a positive, particularly when you consider the complexities of developing new therapies and navigating clinical, regulatory and commercial pathways,\u201d he said.<\/p>\n Carroll said experience gained from working across different companies and therapeutic areas can be incredibly valuable.<\/p>\n \u201cIt allows you to draw on lessons learned, build stronger industry relationships and make more informed decisions as you work towards bringing new treatments to market,\u201d he said.<\/p>\n \u201cThrough my roles at Entropy Neurodynamics and Island Pharmaceuticals, I\u2019ve had the opportunity to work alongside people who bring different backgrounds, expertise and perspectives to the table.\u201d<\/p>\n \u00a0<\/p>\n \ufeff\ufeff\ufeff\ufeff\ufeff\u00a0<\/p>\n \u00a0<\/p>\n The Trimboli connection<\/p>\n TRI chairman David Trimboli\u2019s route into ASX healthcare was less direct. Trimboli is a seasoned investor and a former senior coal trader at Glencore (ASX:GLC)<\/a>, the global commodities giant.<\/p>\n He founded Seefeld Investments, with interests across commodities, industrial minerals, real estate and technology.<\/p>\n He was a seed investor in hearing technology company Audeara (ASX:AUA)<\/a> in 2015 and is now chairman of the board.<\/p>\n Trimboli\u2019s roles continue to stretch beyond healthcare, including as chairman of Aurora Labs (ASX:A3D)<\/a>, which develops additive manufacturing technology for defence, aerospace and industrial applications.<\/p>\n He is also a non-executive director of graphite explorer Quantum Graphite (ASX:QGL)<\/a>.<\/p>\n Trimboli told Stockhead the healthcare sector provided him the opportunity to support innovative technologies with potential to address significant unmet needs, while creating long-term commercial value.<\/p>\n \u201cMy background spans a range of industries, including resources, technology and healthcare, and while each sector has its own challenges, many of the fundamentals of building a successful business remain the same,\u201d he said.<\/p>\n \u201cHaving the right management team, a clear commercial strategy and disciplined capital allocation are critical.<\/p>\n \u201cBiotechnology is a particularly interesting sector because of the complexity and timeframes involved in bringing new technologies to market.<\/p>\n \u201cI think experience gained across different industries can bring a valuable perspective to these businesses, particularly when it comes to financing, managing risk and positioning companies for sustainable growth.\u201d<\/p>\n \u00a0<\/p>\n The Webster branch of the family tree<\/p>\n Experienced biotech leader Dr Nina Webster also has multiple roles. Webster is the CEO and managing director of Dimerix (ASX:DXB)<\/a>, which is undertaking the ACTION3 phase III trial of lead drug DMX-200 to treat rare kidney disease focal segmental glomerulosclerosis (FSGS).<\/p>\n She is also the non-executive chair of SYNthesis BioVentures, which manages a fund focused on early-stage therapeutics, investing in projects from discovery through to preclinical proof of concept and IND-enabling studies.<\/p>\n